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We describe the production of a human induced pluripotent stem cell (iPSC)
line, SFCi55-ZsGr, that has been engineered to express the fluorescent repor-
ter gene, ZsGreen, in a constitutive manner. The CAG-driven ZsGreen
expression cassette was inserted into the AAVS1 locus and a high level of
expression was observed in undifferentiated iPSCs and in cell lineages
derived from all three germ layers including haematopoietic cells, hepato-
cytes and neurons. We demonstrate efficient production of terminally
differentiated macrophages from the SFCi55-ZsGreen iPSC line and show
that they are indistinguishable from those generated from their parental
SFCi55 iPSC line in terms of gene expression, cell surface marker expression
and phagocytic activity. The high level of ZsGreen expression had no effect
on the ability of macrophages to be activated to an M(LPS þ IFNg), M(IL10)
or M(IL4) phenotype nor on their plasticity, assessed by their ability to
switch from one phenotype to another. Thus, targeting of the AAVS1
locus in iPSCs allows for the production of fully functional, fluorescently
tagged human macrophages that can be used for in vivo tracking in disease
models. The strategy also provides a platform for the introduction of factors
that are predicted to modulate and/or stabilize macrophage function.
This article is part of the theme issue ‘Designer human tissue: coming to
a lab near you’.
1. Introduction
The production of functional mature cell types from induced pluripotent stem
cells (iPSCs) is well established as a tool for disease modelling and drug testing
and significant progress is being made for their future use in cell therapy [1,2].
Defined protocols have been described that allow the production of relatively
pure populations of many terminally differentiated cell types including cardio-
myocytes, neurons, hepatocytes, pancreatic beta cells and various cell types
of the haematopoietic lineage [3–10]. The unlimited capacity of iPSCs to
expand in vitro and the advances in genome-editing technology allow them
to be genetically manipulated with ease. Gene knockouts can be performed
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to assess the role of specific genes in healthy or disease states,
cell fate can be modulated by genetic programming and gen-
etic tags can be introduced to allow tracking of therapeutic
cell populations in vivo.
Cells of the monocyte/macrophage lineage have attracted
much attention in the cell therapy field as they have been
shown to have an anti-fibrotic and pro-regenerative effect
in diseases associated with many tissues [11]. For example,
in murine disease models, transplantation of bone marrow-
derived macrophages mediated the progression and recovery
of liver fibrosis [12,13] and improved the disease phenotype
of pulmonary alveolar proteinosis [14]. In the first steps to
translation, the delivery of human macrophages to an immu-
nocompromised mouse model of liver injury improved liver
function and reduced fibrosis [15]. GMP-compliant protocols
have been used to derive autologous macrophages from
patient’s peripheral blood monocytes and these are being
used in the first clinical trial of macrophage cell therapy
[15,16]. However, it is challenging to derive cells from dis-
eased patients and the time taken to produce a sufficient
quantity of therapeutic macrophages severely limits this
approach. Thus, the next logical step is to consider an off-
the-shelf source of macrophages derived from a source such
as iPSCs.
Numerous reports have demonstrated that macrophages
can be generated efficiently from human iPSCs and these
protocols have been adapted to be GMP-compliant [9,17,18].
It has been suggested that iPSC-derived macrophages are
more akin to tissue-resident rather than monocyte-derived
macrophages predicting that they might have even more
powerful therapeutic properties than patient monocyte-
derived cells in some disease settings [18,19]. We demon-
strated that macrophages produced in vitro from mouse
embryonic stem cells (ESCs) were effective in ameliorating
fibrosis in a CCl4-induced liver injury model in vivo, providing
the first proof of concept that this strategy is feasible [18]. We
also showed that ESC-derived macrophages were more effi-
cient at repopulating the Kupffer cell compartment of mice
that had been depleted of macrophages using liposomal
clodronate, providing further support for their phenotype
being comparable to tissue resident macrophages [18].
It has been notoriously difficult to genetically manipulate
primary macrophages, so their production from iPSCs allows
the generation of ‘engineered’ macrophages carrying specific
gene knockouts, genetic factors that might alter their pheno-
type or, as described here, a fluorescent label for their
tracking in vivo. Targeting of transgenes to the AAVS1 locus
of iPSCs and the subsequent differentiation into macrophages
in vitro solves transgene silencing issues that have been
associated with the manipulation of primary macrophages
and cells differentiated from pluripotent cells in vitro [20–22].
Here, we show that neither the targeting of AAVS1 locus
nor the expression of the ZsGreen reporter affects the pro-
duction of macrophages from iPSCs. In addition, this
genetic manipulation has no effect on macrophage function
nor on their ability to be activated into specific phenotypes.
iPSC-derived macrophages retain a degree of plasticity and
this feature is also unaffected by the genetic manipulation
performed in this study. Our data indicate that this powerful
platform could be used to study the therapeutic properties of
macrophages and the ZsGreen-expressing iPSC-derived
macrophages generated in this study could be used to track
these therapeutic cells in vivo.
2. Material and methods
(a) AAVS1-ZsGreen vector construction
ZsGreen1-polyA sequence was amplified from the pZsGreen1-1
vector (Clontech).CAGpromoterwas obtained fromEcoRV-digested
pCAG-IRES-puro plasmid (pCAG-SIP) [23].
Both fragments were inserted to the pZDonor-AAVS1
Puromycin vector (PZD0020, Sigma-Aldrich) to generate the
CAG-ZsGreen-PolyA cassette (figure 1a)
(b) iPSC maintenance and electroporation
The human iPSC line, SFCi55 was generated in-house [24] and
maintained in STEMPROw hESC SFM prepared by supplement-
ing DMEM/F12 (Gibco) with Glutamax (Gibco), StemPro
supplement (Gibco), 1.8% BSA (Gibco), 0.1 mM b-mercaptoetha-
nol (Gibco) and 20 ng ml21 human basic FGF (Invitrogen).
Following electroporation [24], cells were plated on wells pre-
coated with CTSTM CELLstartTM substrate (Gibco) in
STEMPROw hESC SFM containing 20 ng ml21 bFGF and
10 mM Rock inhibitor (Merck) and 0.6 mg ml21 puromycin for
10 days. Puromycin-resistant colonies were picked, expanded
and genomic DNA was extracted using the MasterPureTM com-
plete DNA and RNA purification kit (Epicentre) according to
the manufacturer’s instructions. Genomic DNA was PCR
screened to identify clones with successful integration into the
AAVS1 locus by homologous recombination.
(c) Neuronal differentiation
Neuronal differentiation was initiated by first differentiating for
3 days into neuromesodermal progenitors as described [25].
These were subsequently differentiated into motor neurons
using a protocol based on previously published culture con-
ditions [26] and stained using an anti-tubulin-b3 (TUBB3)
antibody (1 : 1000) (Biolegend).
(d) Hepatocyte differentiation
Adapted from previous reports [6], iPSCs were maintained on
pre-coated laminin 521 (Biolaminin) in serum-free mTeSR1
(STEMCELL Technologies) and plated at a density of 4  104
cells cm22 immediately prior to differentiation. When 40% con-
fluency was reached, differentiation was initiated by replacing
medium with endoderm differentiation medium: RPMI 1640
containing 1  B27 (Life Technologies), 100 ng ml21 Activin A
(PeproTech) and 50 ng ml21 Wnt3a (R&D Systems). Medium
was changed every day for 3 days. On day 3, endoderm differen-
tiation medium was replaced with hepatoblast differentiation
medium: KO-DMEM (Life Technologies), Serum replacement
(Life Technologies), 0.5% Glutamax (Life Technologies), 1%
non-essential amino acids (Life Technologies), 0.2% b-mercap-
toethanol (Life Technologies) and 1% DMSO (Sigma); and
changed every second day for 5 days. On day 8, differentiating
cells were cultured in the hepatocyte maturation medium
HepatoZYME (Life Technologies) containing 1% Glutamax (Life
Technologies), supplemented with 10 ng ml21 hepatocyte
growth factor (PeproTech) and 20 ng ml21 oncostatin M (Pepro-
Tech). Media were renewed every second day for 12 days.
Immunocytochemistry was performed as previously described
[5]. Cytochrome P450 (CYP) activity was assessed. At day 25,
hepatocytes were tested for CYP3A and CYP1A2 activity using
P450-Glo technology (Promega) in accordance with the manu-
facturer’s instructions. CYP activity was expressed as relative
light units per millilitre and normalized by milligrams of protein
(determined by BCA assay, Pierce).
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(e) Colony-forming unit cell assays
Haematopoietic differentiation of iPSCs and CFU-C assays was
performed and scored as previously described [27].
( f ) iPSC cell-derived macrophage production
Adapted from previously published protocols [9,18], iPSC
maintenance medium was changed in one confluent well of
a six-well plate and replaced with 1.5 ml of StemPro hESC
SFM (Gibco) supplemented with 50 ng ml21 BMP4 (R&D),
50 ng ml21 VEGF (R&D) and 20 ng ml21 SCF (Life Technol-
ogies). Cells were passaged into two wells with 2.25 ml of
fresh media using the EZPassageTM tool and embryoid bodies
(EBs) were formed in suspension for 4 days (supplemented
with cytokines on day 2). 10–15 EBs were transferred per well
to a gelatin-coated six-well plate in X-VIVO15 media (3 ml per
well) supplemented with 100 ng ml21 CSF1 (BioLegend),
25 ng ml21 IL3 (Peprotech), 2 mM Glutamax (Gibco), 0.05 mM
b-mercaptoethanol (Gibco) and 1% v/v Penicillin-Streptomycin
(Life Technologies) and media were replaced every three to
four days for three weeks. Monocyte-like precursors were har-
vested from the supernatant (every three to four days for up
to three months) and plated into untreated bacteriological
plates or six-well plates in X-VIVO15 media supplemented
with 100 ng ml21 CSF1 (BioLegend), 2 mM Glutamax
(Gibco) and 1% Penicillin-Streptomycin (Life Technologies) for
9–11 days.
AAVS1
RHA
AAVS1
LHACAG ZsGreen1 polyA polyA PuroR 2A
DAPI TUJ1 ZsG
ZsGBF DAPI albumin
CFU-GEMM 
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ZsG
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BF ZsG BF ZsG
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Figure 1. Expression of ZsGreen in undifferentiated and differentiated SFCi55ZsG iPSCs. (a) Schematic of targeting vector consisting of the CAG constitutive promoter
driving ZeisGreen1 cDNA; the puromycin selectable marker (PuroR), 2A peptide and right (RHA) and left (LHA) homology arms of AAVS1 locus. (b) Bright field (BF)
and fluorescent images (ZsG) of SFCi55-ZsG iPSC (left, 40) and embryoid bodies (EBs) (right, 20). (c) SFCi55-ZsG-derived neurons stained with DAPI and anti-
TUJ1 antibody (20). (d ) SFCi55-ZsG-derived hepatocytes stained with DAPI and albumin antibody (40). (e) Bright field and fluorescent images of haemato-
poietic colonies generated in methylcellulose from SFCi55-ZsG (40). Colony-forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM), burst
forming unit erythroid (BFU-E), colony-forming unit, granulocyte, (CFU-G), colony-forming unit, macrophage (CFU-M); (Scale bars, 100 mm).
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(g) Cytospins and rapid-chrome Kwik-Diff staining
Cells were harvested, re-suspended in PBS (2.5  104 ml21) and
cyto-centrifuged at 72g for 7 min in a Thermo Shandon Cytospin
4 onto polylysine slides. After air-drying overnight, cells were
stained with Kwik-Diff Staining according to the manufacturer’s
instructions (Thermo-Fisher)
(h) Macrophage activation and plasticity
Adherent iPSC-derived macrophages were activated in vitro to
three different phenotypes by treating them for 48 h with either
0.1 mg ml21 LPS (Sigma) and 10 U ml21 IFNg (eBioscience),
20 ng ml21 IL-4 (Preprotech) or 5 ng ml21 IL-10 (Preprotech). In
experiments designed to test macrophage plasticity, cells were
activated in the first condition for 48 h then media was changed
to the second condition for a further 48 h.
(i) Quantitative real-time PCR
Total RNA was extracted using the RNAeasy Mini Kit (Qiagen);
cDNA was generated from 500 ng or 1 mg of total RNA using
the High Capacity cDNA synthesis Kit (Applied Biosystems).
Two nanograms of cDNA was amplified per reaction and each
reaction was performed in three technical replicates using the
LightCycler 384 (Roche) with SYBR Green Master Mix II (Roche)
and appropriate primers (electronic supplementary material,
table S1). For gene expression analyses, GAPDH, b-ACTIN and
B2M were used as reference genes and the geometrical mean
was used to normalize the data.
( j) Flow cytometry
Macrophages were detached using StemPro Accutase Cell
Dissociation Reagent (Gibco), re-suspended and blocked with
FcR Blocking Reagent (MACS) according to the manufacturer’s
instructions. 1  105 cells were washed, stained with appropriate
antibodies (electronic supplementary material, table S2) for
20 min at room temperature then washed within PBS with 1%
BSA and 5 mM EDTA, then analysed using LSR Fortessa
Analyser (BD) and FlowJo v. 10.2. Dead cells were gated out
using DAPI.
(k) Phagocytosis assay
Live imaging of phagocytosis was carried out as we described
previously in [18] with some modifications to allow the use of
pHrodoTM Red Zymosan BioParticles for the analysis of
SFCi55-ZsG macrophages. SFCi55-ZsG macrophages were
stained with Hoechst33342 1 : 20 (Thermo-Fisher) for 20 min at
37 8C. A vial of pHrodoTM Red Zymosan BioParticles was re-sus-
pended in 2 ml of PBS and diluted 1 : 5. Imaging was performed
on the Operetta High-Content Imaging System (Perkin-Elmer) at
5 min intervals for 175 min, at 40 magnification.
(l) Statistical analyses
Results are expressed as mean+ s.e.m. Specific statistical tests
(as stated in figure legends) were performed using Graph
Pad software v. 6.0c. p-values less than 0.05 were considered
statistically significant (*p, 0.05, **p, 0.01, ***p , 0.001,
****p, 0.0001).
3. Results
(a) Production of SFCi55ZsG iPSC line
SFCi55 iPSCs were electroporated with the pZDonor-AAVS1-
ZsGreen vector (figure 1a) and a plasmid expressing the
AAVS1-specific zinc finger nuclease and selected in puromy-
cin as previously described [24]. Genomic DNA isolated
from puromycin-resistant clones was screened by PCR to
identify clones in which the targeting vector had integrated
into the AAVS1 locus by homologous recombination. Over
90% of puromycin-resistant clones carried the correct target-
ing event (electronic supplementary material, figure S1A, B)
and several clones were expanded and characterized. The
specific clone, herein referred to as SFCi55ZsG, was shown
to have a normal karyotype and retained the ability to
generate cells of all three germ layers.
(b) Expression of ZsGreen in undifferentiated iPSCs and
in cells of all three germ layers
ZsGreen was expressed at high levels in all undifferentiated
SFCi55-ZsGr iPSCs when grown in maintenance conditions
(figure 1b). To assess whether the expression of ZsGreen per-
sisted in terminally differentiated cells, we analysed the
expression in EBs and in mature cells derived from all three
germ layers. The SFCi55-ZsGr iPSCs line could be differen-
tiated into cell types associated with all three germ layers.
ZsGreen continues to be expressed at high levels in TUJ1-
postiive neuronal cells (figure 1c) and in albumin-positive
hepatocyte-like cells (figure 1d ). CYP3A and CYP1A2 activity
was detected in SFCi55-ZsG iPSCs-derived hepatocyte-like
cells by luminescence (electronic supplementary material,
figure S1C) and the level of activity of these cytochrome
P450 enzymes was comparable to that observed for hepato-
cyte-like cells derived from other pluripotent stem cell lines
(data not shown)
Differentiating SFCi55-ZsG iPSCs were cultured in semi-
solid CFU-C culture conditions to examine the haematopoietic
colony-forming unit (CFU-C) derived from haematopoietic
progenitors [27]. ZsGreen was expressed in a wide range of
haematopoietic cell types generated under these conditions
including cells of the erythroid, granulocytic and macro-
phage lineages (figure 1e). We then focused our study on
the phenotypic and functional properties of macrophages.
(c) SFCi55-ZsG-derived macrophages are comparable to
control cells
Macrophages generated from SFCi55-ZsG iPSCs had a simi-
lar morphology to macrophages derived from control
SFCi55 iPSCs (figure 2a). Both lines generated approximately
5  106 macrophages per six-well plate at each harvest indi-
cating that the expression of ZsGreen had no significant
effect on the efficiency of differentiation. All macrophages
generated from the SFCi55-ZsGr iPSC line expressed ZsGreen
at high levels (figure 2b; electronic supplementary material,
figure S1D). The cell surface marker expression of mono-
cyte-like and mature macrophages derived from SFCi55-
ZsGr iPSCs was indistinguishable from those derived from
the parental iPSC line (figure 2c; electronic supplementary
material, figure S2A). When monocyte-like cells were first
harvested, they expressed CD45 and CD93 but as they
matured in culture, they gained expression of 25F9 and lost
CD93 expression, as expected (figure 2c; electronic sup-
plementary material, figure S2A). Expression of CD169 and
CD163 was heterogeneous in macrophages derived from
both cell lines (figure 2d; electronic supplementary material,
figure S2B). We compared the expression of genes associated
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Figure 2. SFCi55-ZsG Macrophages are phenotypically comparable to control macrophages. (a) Cytospins of macrophages (Mf ) derived from SFCi55 (parental line)
and SFCi55-ZsG iPSCs (40). (b) Bright field (BF) and green channel (ZsG) images of SFCi55-ZsG macrophages (40). (c) Flow Cytometry analysis of CD45, CD93
and 25F9 expression in SFCi55 macrophages (left) and SFCi55-ZsG macrophages (right). (d ) Quantification of flow cytometry analysis of CD163 and CD169 expression
in SFCi55 and SFCi55-ZsG macrophages (n ¼ 5, Mann–Whitney test). (e) Quantitation RT-PCR analyses of RNA isolated from monocyte-derived macrophages (MDM)
and macrophages derived from the SFCi55 and SFCi55-ZsG iPSCs assessing the level of expression of genes associated with tissue resident macrophage genes (MAF)
and monocyte-derived macrophages (CCR2, FLT3, PU.1). (n ¼ 6, Kruskal–Wallis test with Dunn’s multiple comparisons post-test) (*p, 0.05). ( f ) Quantification of
flow cytometry analyses of cell-surface marker expression in macrophages derived from SFCi55 and SFCi55-ZsG iPSCs (n ¼ 5 for all except CD115 and CD206; n ¼
3); maturation markers (n ¼ 5), immune modulation markers (n ¼ 3), Fc receptors (n ¼ 3) and chemokine receptors (n ¼ 3); Mann–Whitney test.
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with monocyte/macrophage development and differentiation
in iPSC-derived macrophages with monocyte-derived macro-
phages (MDM). The monocyte markers CCR2 and PU.1 are
expressed at low levels in mature iPSC-derived macrophages
from both lines compared with MDM (figure 2e). By contrast,
a higher level of expression of MAF was observed in iPSC-
derived cells, indicating that iPSC-derived macrophages are
more comparable to tissue-resident macrophages [19]
(figure 2e). We quantified the expression of specific cell surface
markers associated with macrophage differentiation (CD45,
CD115, CD206, CD11b, CD169, CD43 and CD14) and matu-
ration (CD93, 25F9) as well as immune modulators (CD274,
HLA-DR, CD86), Fc receptors (CD16, CD64) and chemokine
receptors (CX3CR1, CCR2, CCR5, CCR8) on both SFCi55 and
SCFi55–ZsG macrophages and observed a comparable pro-
portion of cells expressing these markers (figure 2f) and a
comparable level of marker expression per cell (electronic
supplementary material, figure S3).
(d) SFCi55-ZsG-derived macrophages are functional, can
be activated and retain plasticity
Phagocytosis is one of the defining features of a functional
macrophage and the rate of phagocytosis is closely associated
with specific phenotypic states. We assessed phagocytosis in
macrophages derived from SFCi55 and SFCi55-ZsG by live
imaging using green and red Phrodo beads, respectively
[18]. This strategy provides a quantitative measure of phago-
cytosis in real time and enables direct comparison between
macrophages derived from different iPSC lines.
Comparable rates of phagocytosis were observed in naive
macrophages derived from the SFCi55 and SFCi55-ZsG iPSC
lines, indicating that the genetic manipulation had no func-
tional consequences and that the sensitivity of the assay
using the green and red Phrodo beads was comparable.
In response to environmental cues, macrophages have the
ability to be activated to a specific functional state and to
retain the ability to switch between these states [28,29]. To
assess these features of iPSC-derived cells, macrophages
derived from the SFCi55 and SFCi55-ZsG iPSCs were acti-
vated to three different phenotypes by treating with LPS
and IFNg, IL-4 and IL-10. These phenotypes are herein
referred to as M(LPS þ IFNg), M(IL4) and M(IL10) [29].
When macrophages were activated with LPS and IFNg or
IL-4, phagocytosis was significantly reduced compared with
naive cells and this was evident in macrophages derived from
both control and ZsGreen-expressing iPSCs (figure 3a–c; elec-
tronic supplementary material, figure S4). By contrast, when
activatedwith IL10, a higher rate of phagocytosis was observed
(figure 3a–c) and, again no significant difference in the
response of SFCi55- and SFCi55ZsG-derived macrophages
was observed (figure 3a–c). The activated phenotypes were
confirmed by expression of genes encoding markers associated
with M(LPS þ IFNg) macrophages (CD40, CD80, VCAM1,
TNF-a) and M(IL10) or M(IL4) macrophages (CD84, CD68,
TGM2, MRC1) and the expression levels of these genes were
comparable between macrophages derived from the two iPSC
lines (figure 3d). These data confirm that iPSC-derived macro-
phages can be activated effectively and that the high level
of expression of ZsGreen in these macrophages had no detri-
mental effect on phagocytic function and on the ability of
cells to be activated.
The plastic nature of macrophages is widely accepted, but
this feature has not been tested directly in iPSC-derivedmacro-
phages. To assesswhether iPSC-derivedmacrophages retained
plasticity, they were first activated with IFNg and LPS for 48 h
then the medium was replaced with that containing IL10.
The reciprocal experiment was also performed where IL10-
activated macrophages were switched to M(IFNg þ LPS)-
inducing conditions. Our quantitative phagocytosis assay
demonstrates that LPS and IFNg-induced iPSC-derivedmacro-
phages could be counter-activated to an M(IL10)-like
phenotype and that the rate of phagocytosis was equivalent
to macrophages that had been polarized with IL10 directly
(figure 3e,g). Likewise, the rate of phagocytosis ofmacrophages
that were first activated using IL10 then counter-activatedwith
LPS and IFNg was comparable to that of cells that had been
activated with LPS and IFNg only (figure 3e,g). Comparable
data were obtained with macrophages derived from the
SFCi55ZsG cell line, indicating that neither targeting of the
AAVS1 locus nor the high levels of ZsGreen expression affect
the plasticity of iPSC-derived macrophages (figure 3f,g).
4. Discussion
Rapid advances over the past 10 years in the production of
iPSCs and in the design of defined differentiation conditions
have led to an enormous increase in the use of iPSC-derived
cell types in drug testing and disease modelling [30]. Pro-
duction and differentiation of patient-specific iPSCs has led
to advances in the understanding and treatment of a wide
range of genetic disorders. There has also been progress in
the use of iPSC-derived cells in cell replacement therapies
with recent reports describing the use of iPSC-derived retinal
pigment epithelial cells in a few clinical case studies [31].
Several factors are inhibiting the clinical translation of iPSC-
derived cell therapies including the significant safety issues con-
cerning their genetic stability, the persistence of residual
tumour-initiating iPSCs and the functional properties of the
cells that are generated. The lack of appropriate animal
models where therapeutic cells can be tracked, their efficacy
monitored and theirmechanismof action elucidated has further
hampered progress [2,30]. As a first step to address some of
these issues, we have tested a platform where transgenes can
be inserted into a defined site in the iPSC genome and have cre-
ated a genetically engineered iPSC line that expresses the
ZsGreen fluorescent reporter. Targeting the reporter gene to
the ‘safe harbour’, AAVS1 locus, ensures that the reporter
gene is not silenced and continues to be expressed inmature dif-
ferentiated cells. This directed targeting strategy also ensures
that the genetic manipulation could be reproduced in patient-
specific iPSCs and importantly it reduces the risk of unwanted
insertion mutagenesis that would be associated with random
integration of transgenes into the genome.
The SFCi55-ZsG iPSC line can be differentiated into cells
associated with all three primary germ layers and expression
of the ZsGreen reporter persists in terminally differentiated
TUJ1-expressing neurons, in albumin-expressing hepato-
cyte-like cells and in all cells of the haematopoietic lineage.
ZsGreen-expressing hepatocytes had comparable cytochrome
P450 activity to hepatocytes derived from other pluripotent
stem cells, indicating that the genetic manipulation did not
have a detrimental effect on cell function.
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The therapeutic effect of macrophages has been demon-
strated in animal models of fibrosis [12–14], but it has
proved difficult to track these cells in vivo and there is a poor
understanding of their mechanism of action. Translating the
therapeutic effects of macrophages from animal models into
human is becoming a real clinical need in different fields of
investigation, such as cancer and inflammation. To date, the
main strategies used to generate human macrophages in vitro
have relied on pro- and monocytic cell lines such as U937,
THP1 and Mono-mac cell lines [32–34] and monocyte-derived
macrophages from peripheral blood monocytes [35,36]. Both
systems are currently accepted and widely used in research,
but they have significant limitations. Although cell lines are
easy to culture, transfect and genetically modify, they are
immortalized cells and thus may not fully represent primary
human macrophages. Although MDM are likely to be more
comparable to those found in vivo, the number of cells that
can be generated is limited, there is significant variability
between donors and they have proved difficult to genetically
modify which is partly due to their expression of restriction
factors that limit lentiviral integration [37]. Thus, the ability
to generate functional macrophages from a limitless source
of iPSCs that can be genetically manipulated represents a
significant advance in the field.
A previous study reported the generation of macrophages
from GFP-expressing iPSCs, but although this study demon-
strated that GFP-expressing macrophages could be produced,
no detailed functional comparisons were performed [22]. Our
study demonstrates clearly that the macrophages produced
from genetically engineered iPSCs are fully functional and
indistinguishable from those generated from control iPSCs.
We show that AAVS1 targeting does not affect the production
and function of iPSC-derived macrophages and, as the
ZsGreen reporter is brighter than eGFP [38], we predict it
to be a more sensitive strategy for in vivo tracking.
Macrophages can be activated to a whole spectrum of phe-
notypic states and can be modulated between these states
depending on the microenvironment [28,29]. The local niche
within a repairing and regenerating tissue is likely to be
highlydynamic and thephenotypeof transplanted ‘therapeutic’
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Figure 3. SFCi55-ZsG Macrophages are functional, can be activated and retain plasticity. (a,b) Fraction of phagocytic cells over time for SFCi55-derived (a) or SFCi55-
ZsG-derived (b) macrophages (mf ) in the naive state and activated using LPS þ IFNg, IL10 or IL4 (n ¼ 6, two-way ANOVA and Dunnette’s multiple comparisons
post-test). (c) Quantification of phagocytic fractions (data from a and b) from SFCi55 and SFCi55-ZsG-derived macrophages in naı¨ve and activated states (n ¼ 6,
Kruskal–Wallis test and Dunn’s multiple comparisons post-test). (d ) Quantitative RT-PCR of RNA isolated from naive and polarized macrophages derived from SFCi55
and SFCi55-ZsG macrophages to assess the expression of M(LPS þ IFNg) and M(IL10)-associated genes upon stimulation (n ¼ 6, key to colours as in (a)). One-way
ANOVA and Holm-Sidak’s multiple comparisons post-test). (e,f ) Fraction of phagocytic cells over time for SFCi55-ZsG macrophages (e) and SFCi55-ZsG macrophages
( f ) under M(LPS þ IFNg) and M(IL10) conditions only and where they were switched from M(LPS þ IFNg) to M(IL10) or M(IL10) to M(LPS þ IFNg) conditions
(n ¼ 6, two-way ANOVA and Tukey’s multiple comparisons post-test). (g) Quantification of phagocytic fractions (e,f data) from SFCi55 and SFCi55-ZsG macrophages
in experiments designed to assess plasticity (n ¼ 6, Kruskal–Wallis test and Dunn’s multiple comparisons post-test) (*p, 0.05, **p, 0.01, ***p, 0.001,
****p , 0.0001).
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cells will inevitably be influenced by that ever-changing
environment. We demonstrate that iPSC-derived macrophages
are capable of responding appropriately to environmental
cues and can switch readily between phenotypes indicating
that they could have a powerful therapeutic effect. The fact
that they can be genetically manipulated also makes it possible
to modulate their phenotype by genetic programming. The
identification of programming factors and the stable expression
of these using AAVS1 targeting technology could lock macro-
phages into a desired phenotype and/or modulate how they
respond to the regenerating environment in vivo.
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